recombinant human laminin-111

Recombinant human laminin-111 (rhLAM-111) is an investigational recombinant protein replacement therapy designed to treat rare, life-threatening neuromuscular disorders, specifically laminin-α2-related congenital muscular dystrophy (LAMA2-CMD) and Duchenne muscular dystrophy (DMD). Laminin-111 is an embryonic isoform of laminin that is structurally and functionally homologous to laminin-211/221, which is deficient or absent in LAMA2-CMD. By acting as a molecular surrogate, rhLAM-111 binds to key cell-surface receptors, including α7β1-integrin and the dystrophin-glycoprotein complex, thereby restoring cell-matrix adhesion, stabilizing the muscle cell membrane, reducing apoptosis, and promoting muscle regeneration. Originally discovered at the University of Nevada, Reno, and initially developed by Prothelia, the program was acquired by Sarcomatrix Therapeutics in May 2024 and has been granted Orphan Drug Designation in both the United States and the European Union.

Other names

laminin-111 (human)rLaminin-111rLaminin111rLaminin 111recombinant human laminin-111 protein